1.Chalasani, N, Younossi, Z, Lavine, JE et al. (2018) the diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology 67, 328–357.
2.Diehl, AM & Day, C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377, 2063–2072.
3.Nasr, P, Ignatova, S, Kechagias, S et al. (2018) Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun 2, 199–210.
4.Cholankeril, G, Wong, RJ, Hu, M et al. (2017) Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci 62, 2915–2922.
5.Williams, R, Aspinall, R, Bellis, M et al. (2014) Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384, 1953–1997.
6.Wong, VW, Chitturi, S, Wong, GL et al. (2016) Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 1, 56–67.
7.EASL-EASD-EASO (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64, 1388–1402.
9.Schwenzer, NF, Springer, F, Schraml, C et al. (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51, 433–445.
10.Browning, JD, Szczepaniak, LS, Dobbins, R et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395.
11.Sanyal, AJ, Brunt, EM, Kleiner, DE et al. (2011) Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54, 344–353.
12.Younossi, ZM, Koenig, AB, Abdelatif, D et al. (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84.
13.Alberti, KG, Eckel, RH, Grundy, SM et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645.
14.Younossi, Z, Anstee, QM, Marietti, M et al. (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15, 11–20.
15.Fan, JG, Kim, SU & Wong, VW (2017) New trends on obesity and NAFLD in Asia. J Hepatol 67, 862–873.
16.Bialek, SR, Redd, JT, Lynch, A et al. (2008) Chronic liver disease among two American Indian patient populations in the southwestern United States, 2000–2003. J Clin Gastroenterol 42, 949–954.
17.Schwimmer, JB, Celedon, MA, Lavine, JE et al. (2009) Heritability of nonalcoholic fatty liver disease. Gastroenterology 136, 1585–1592.
18.Loomba, R, Schork, N, Chen, CH et al. (2015) Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 149, 1784–1793.
19.Moore, JB (2010) Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 69, 211–220.
20.Ekstedt, M, Hagstrom, H, Nasr, P et al. (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554.
21.Hagstrom, H, Nasr, P, Ekstedt, M et al. (2017) Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 67, 1265–1273.
22.Pais, R, Charlotte, F, Fedchuk, L et al. (2013) A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59, 550–556.
23.Cohen, JC, Horton, JD & Hobbs, HH (2011) Human fatty liver disease: old questions and new insights. Science 332, 1519–1523.
24.Piscaglia, F, Svegliati-Baroni, G, Barchetti, A et al. (2016) Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 63, 827–838.
25.Mittal, S, El-Serag, HB, Sada, YH et al. (2016) Hepatocellular Carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 14, 124–131.
26.Stine, JG, Wentworth, BJ, Zimmet, A et al. (2018) Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Ailment Pharmacol Ther 48, 696–703.
27.Bhaskaran, K, Douglas, I, Forbes, H et al. (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384, 755–765.
28.D'Avola, D, Labgaa, I & Villanueva, A (2016) Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: magnitude of the problem from a hepatology clinic perspective. Clinical Liver Disease 8, 100–104.
29.Angulo, P, Kleiner, DE, Dam-Larsen, S et al. (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.
30.Rowe, IA (2018) Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 3, 66–72.
31.Koehler, EM, Plompen, EP, Schouten, JN et al. (2016) Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 63, 138–147.
32.Estes, C, Razavi, H, Loomba, R et al. (2018) Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133.
33.Lonardo, A, Nascimbeni, F, Mantovani, A et al. (2018) Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68, 335–352.
34.Day, CP & James, OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842–845.
35.Buzzetti, E, Pinzani, M & Tsochatzis, EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038–1048.
36.Eslam, M, Valenti, L & Romeo, S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68, 268–279.
37.Neuschwander-Tetri, BA (2010) Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52, 774–788.
38.Marra, F & Svegliati-Baroni, G (2018) Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68, 280–295.
39.Mashek, DG (2013) Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr 4, 697–710.
40.Gluchowski, NL, Becuwe, M, Walther, TC et al. (2017) Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol 14, 343–355.
41.Martinez-Lopez, N & Singh, R (2015) Autophagy and lipid droplets in the liver. Annu Rev Nutr 35, 215–237.
42.Greenberg, AS, Coleman, RA, Kraemer, FB et al. (2011) The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest 121, 2102–2110.
43.Schuppan, D, Surabattula, R & Wang, XY (2018) Determinants of fibrosis progression and regression in NASH. J Hepatol 68, 238–250.
44.Sunny, NE, Parks, EJ, Browning, JD et al. (2011) Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 14, 804–810.
45.Romeo, S, Kozlitina, J, Xing, C et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40, 1461–1465.
46.Anstee, QM, Seth, D & Day, CP (2016) Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 150, 1728–1744.
47.Tian, C, Stokowski, RP, Kershenobich, D et al. (2010) Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42, 21–23.
48.Trepo, E, Pradat, P, Potthoff, A et al. (2011) Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54, 60–69.
49.Liu, YL, Patman, GL, Leathart, JB et al. (2014) Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 61, 75–81.
50.He, S, McPhaul, C, Li, JZ et al. (2010) A sequence variation (I148 M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285, 6706–6715.
51.Huang, Y, Cohen, JC & Hobbs, HH (2011) Expression and characterization of a PNPLA3 protein isoform (I148 M) associated with nonalcoholic fatty liver disease. J Biol Chem 286, 37085–37093.
52.Pirazzi, C, Adiels, M, Burza, MA et al. (2012) Patatin-like phospholipase domain-containing 3 (PNPLA3) I148 M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 57, 1276–1282.
53.Trepo, E, Romeo, S, Zucman-Rossi, J et al. (2016) PNPLA3 gene in liver diseases. J Hepatol 65, 399–412.
54.Kozlitina, J, Smagris, E, Stender, S et al. (2014) Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46, 352–356.
55.Dongiovanni, P, Petta, S, Maglio, C et al. (2015) Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61, 506–514.
56.Buch, S, Stickel, F, Trepo, E et al. (2015) A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 47, 1443–1448.
57.Luukkonen, PK, Zhou, Y, Hyotylainen, T et al. (2016) The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 65, 1263–1265.
58.Mancina, RM, Dongiovanni, P, Petta, S et al. (2016) The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology 150, 1219–1230.
59.Donati, B, Dongiovanni, P, Romeo, S et al. (2017) MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep 7, 4492.
60.Speliotes, EK, Yerges-Armstrong, LM, Wu, J et al. (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7, e1001324.
61.Santoro, N, Zhang, CK, Zhao, H et al. (2012) Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55, 781–789.
62.Petta, S, Miele, L, Bugianesi, E et al. (2014) Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS ONE 9, e87523.
63.Beer, NL, Tribble, ND, McCulloch, LJ et al. (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18, 4081–4088.
64.Koo, BK, Joo, SK, Kim, D et al. (2018) Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 33, 1277–1285.
65.Abul-Husn, NS, Cheng, X, Li, AH et al. (2018) A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 378, 1096–1106.
66.Su, W, Wang, Y, Jia, X et al. (2014) Comparative proteomic study reveals 17beta-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 111, 11437–11442.
67.Stender, S, Kozlitina, J, Nordestgaard, BG et al. (2017) Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49, 842–847.
68.Kenneally, S, Sier, JH & Moore, JB (2017) Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ Open Gastroenterol 4, e000139.
69.Heymsfield, SB & Wadden, TA (2017) Mechanisms, pathophysiology, and management of obesity. N Engl J Med 376, 254–266.
70.Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L et al. (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378.
71.Katsagoni, CN, Georgoulis, M, Papatheodoridis, GV et al. (2017) Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis. Metabolism 68, 119–132.
72.Franz, MJ, Boucher, JL, Rutten-Ramos, S et al. (2015) Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 115, 1447–1463.
73.Eslamparast, T, Tandon, P & Raman, M (2017) Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease. Nutrients 9, 800.
74.Sargeant, JA, Gray, LJ, Bodicoat, DH et al. (2018) The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis. Obes Rev 19, 1446–1459.
75.Zelber-Sagi, S, Nitzan-Kaluski, D, Goldsmith, R et al. (2008) Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48, 1791–1798.
76.Gleeson, M, Bishop, NC, Stensel, DJ et al. (2011) The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11, 607–615.
77.Carson, BP (2017) The potential role of contraction-induced myokines in the regulation of metabolic function for the prevention and treatment of type 2 diabetes. Front Endocrinol (Lausanne) 8, 97.
78.Rees, K, Hartley, L, Flowers, N et al. (2013) ‘Mediterranean’ dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 8, .
79.Garcia, M, Bihuniak, JD, Shook, J et al. (2016) The effect of the traditional mediterranean-style diet on metabolic risk factors: a meta-analysis. Nutrients 8, 168.
80.Rosato, V, Temple, NJ, La Vecchia, C et al. (2017) Mediterranean diet and cardiovascular disease: a systematic review and meta-analysis of observational studies. Eur J Nutr [Epublication ahead of print version].
81.Zelber-Sagi, S, Salomone, F & Mlynarsky, L (2017) The mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms. Liver Int 37, 936–949.
82.Estruch, R, Ros, E, Salas-Salvado, J et al. (2018) Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 378, e34.
83.Ryan, MC, Itsiopoulos, C, Thodis, T et al. (2013) The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59, 138–143.
84.Properzi, C, O'Sullivan, TA, Sherriff, JL et al. (2018) Ad libitum mediterranean and low fat diets both significantly reduce hepatic steatosis: a randomized controlled trial. Hepatology 68, 1741–1754.
85.Moore, JB, Gunn, PJ & Fielding, BA (2014) The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients 6, 5679–5703.
86.Moore, JB & Fielding, BA (2016) Sugar and metabolic health: is there still a debate? Curr Opin Clin Nutr Metab Care 19, 303–309.
87.Luukkonen, PK, Sadevirta, S, Zhou, Y et al. (2018) Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care 41, 1732–1739.
88.Wise, J (2017) Major report backs overhaul of US dietary guideline process. BMJ 358, j4340.
89.Teicholz, N (2015) The scientific report guiding the US dietary guidelines: is it scientific? BMJ 351, h4962.
90.National Center for Health Statistics USA (2017) .
92.Maldonado, EM, Fisher, CP, Mazzatti, DJ et al. (2018) Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease. npj Syst Biol Appl 4, 33.
93.Clifton, P (2013) We need more data before rejecting the saturated fat hypothesis. BMJ 347, f6847.
94.Lim, DC (2013) Sugar, not fat, is the culprit. BMJ 347, f6846.
95.Moore, JB, Horti, A & Fielding, BA (2018) Evaluation of the nutrient content of yogurts: a comprehensive survey of yogurt products in the major UK supermarkets. BMJ Open 8, e021387.
96.Mager, DR, Iniguez, IR, Gilmour, S et al. (2013) The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD). JPEN 39, 73–84.
97.Volynets, V, Machann, J, Kuper, MA et al. (2013) A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study. Eur J Nutr 52, 527–535.
98.Goran, MI & Ventura, EE (2012) Genetic predisposition and increasing dietary fructose exposure: the perfect storm for fatty liver disease in Hispanics in the U.S. Dig Liver Dis 44, 711–713.
99.Johnston, RD, Stephenson, MC, Crossland, H et al. (2013) No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 145, 1016–1025 .
100.Chiu, S, Sievenpiper, JL, de Souza, RJ et al. (2014) Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 68, 416–423.
101.Schwimmer, JB, Ugalde-Nicalo, P, Welsh, JA et al. (2019) Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA 321, 256–265.
102.Zelber-Sagi, S, Nitzan-Kaluski, D, Goldsmith, R et al. (2007) Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47, 711–717.
103.Musso, G, Gambino, R, De Michieli, F et al. (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909–916.
104.Musa-Veloso, K, Venditti, C, Lee, HY et al. (2018) Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. Nutr Rev 76, 581–602.
105.Yan, JH, Guan, BJ, Gao, HY et al. (2018) Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Medicine 97, e12271.
106.Scorletti, E, Bhatia, L, McCormick, KG et al. (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology 60, 1211–1221.
107.Perumpail, BJ, Li, AA, John, N et al. (2018) The role of vitamin e in the treatment of NAFLD. Diseases 6, 86.
108.Singh, S, Khera, R, Allen, AM et al. (2015) Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 62, 1417–1432.
109.Sawangjit, R, Chongmelaxme, B, Phisalprapa, P et al. (2016) Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine 95, e4529.
110.Said, A & Akhter, A (2017) Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol 16, 538–547.
111.Kitson, MT & Roberts, SK (2012) D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 57, 897–909.
112.Kwok, RM, Torres, DM & Harrison, SA (2013) Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology 58, 1166–1174.
113.Eliades, M, Spyrou, E, Agrawal, N et al. (2013) Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 38, 246–254.
114.Gibson, PS, Lang, S, Gilbert, M et al. (2015) Assessment of diet and physical activity in paediatric non-alcoholic fatty liver disease patients: a united kingdom case control study. Nutrients 7, 9721–9733.
115.Gibson, PS, Quaglia, A, Dhawan, A et al. (2018) Vitamin D status and associated genetic polymorphisms in a cohort of UK children with non-alcoholic fatty liver disease. Pediatr Obes 13, 433–441.
116.Barchetta, I, Cimini, FA & Cavallo, MG (2017) Vitamin D supplementation and non-alcoholic fatty liver disease: present and future. Nutrients 9, 1015.
117.Sharifi, N & Amani, R (2017) Vitamin D supplementation and non-alcoholic fatty liver disease: a critical and systematic review of clinical trials. Crit Rev Food Sci Nutr https://doi.org/10.1080/10408398.2017.1389693.
118.Nelson, JE, Roth, CL, Wilson, LA et al. (2016) Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: possible role for MAPK and NF-kappaB? Am J Gastroenterol 111, 852–863.
119.Bril, F, Maximos, M, Portillo-Sanchez, P et al. (2015) Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J Hepatol 62, 405–411.
120.Jaruvongvanich, V, Ahuja, W, Sanguankeo, A et al. (2017) Vitamin D and histologic severity of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis 49, 618–622.
121.Powe, CE, Evans, MK, Wenger, J et al. (2013) Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369, 1991–2000.
122.Abramovitch, S, Dahan-Bachar, L, Sharvit, E et al. (2011) Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 60, 1728–1737.
123.Ding, N, Yu, RT, Subramaniam, N et al. (2013) A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601–613.
124.Beilfuss, A, Sowa, JP, Sydor, S et al. (2015) Vitamin D counteracts fibrogenic TGF-beta signalling in human hepatic stellate cells both receptor-dependently and independently. Gut 64, 791–799.
125.Skoien, R, Richardson, MM, Jonsson, JR et al. (2013) Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 33, 624–632.
126.Moore, JB & Weeks, ME (2011) Proteomics and systems biology: current and future applications in the nutritional sciences. Adv Nutr 2, 355–364.
127.Kitano, H (2002) Computational systems biology. Nature 420, 206–210.
128.Stephanou, A, Fanchon, E, Innominato, PF et al. (2018) Systems biology, systems medicine, systems pharmacology: the what and the why. Acta Biotheor 66, 345–365.
129.Nielsen, J (2017) Systems biology of metabolism: a driver for developing personalized and precision medicine. Cell Metab 25, 572–579.
130.Hood, L, Heath, JR, Phelps, ME et al. (2004) Systems biology and new technologies enable predictive and preventative medicine. Science 306, 640–643.
131.Hood, L & Flores, M (2012) A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 29, 613–624.
132.de Graaf, AA, Freidig, AP, De Roos, B et al. (2009) Nutritional systems biology modeling: from molecular mechanisms to physiology. PLoS Comput Biol 5, e1000554.
133.Ordovas, JM, Ferguson, LR, Tai, ES et al. (2018) Personalised nutrition and health. BMJ 361, .
134.de Roos, B & Brennan, L (2017) Personalised interventions-a precision approach for the next generation of dietary intervention studies. Nutrients 9, 847.
135.Grimaldi, KA, van Ommen, B, Ordovas, JM et al. (2017) Proposed guidelines to evaluate scientific validity and evidence for genotype-based dietary advice. Genes Nutr 12, 35.
136.Jerby, L, Shlomi, T & Ruppin, E (2010) Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol 6, 401.
137.Gille, C, Bölling, C, Hoppe, A et al. (2010) HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol 6, 1–13.
138.Mardinoglu, A, Agren, R, Kampf, C et al. (2014) Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun 5, 3083.
139.Uhlen, M, Oksvold, P, Fagerberg, L et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28, 1248–1250.
140.Fisher, CP, Plant, NJ, Moore, JB et al. (2013) QSSPN: dynamic simulation of molecular interaction networks describing gene regulation, signalling and whole-cell metabolism in human cells. Bioinformatics 29, 3181–3190.
141.Fisher, CP, Kierzek, AM, Plant, NJ et al. (2014) Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 20, 15070–15078.
142.Maldonado, EM, Leoncikas, V, Fisher, CP et al. (2017) Integration of genome scale metabolic networks and gene regulation of metabolic enzymes with physiologically based pharmacokinetics. CPT: Pharmacometrics & Syst Pharmacol. 6, 732–746.
143.Mardinoglu, A, Bjornson, E, Zhang, C et al. (2017) Personal model-assisted identification of NAD + and glutathione metabolism as intervention target in NAFLD. Mol Syst Biol 13, 916.
144.Pamuk, GE & Sonsuz, A (2003) N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 18, 1220–1221.
145.Khoshbaten, M, Aliasgarzadeh, A, Masnadi, K et al. (2010) N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease. Hepat Mon 10, 12–16.
146.Malaguarnera, M, Gargante, MP, Russo, C et al. (2010) L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. Am J Gastroenterol 105, 1338–1345.
147.Somi, MH, Fatahi, E, Panahi, J et al. (2014) Data from a randomized and controlled trial of LCarnitine prescription for the treatment for non- alcoholic fatty liver disease. Bioinformation 10, 575–579.
148.Yamakado, M, Tanaka, T, Nagao, K et al. (2017) Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors. Sci Rep 7, 14485.
149.Gaggini, M, Carli, F, Rosso, C et al. (2018) Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology 67, 145–158.
150.Hyotylainen, T, Jerby, L, Petaja, EM et al. (2016) Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nat Commun 7, 8994.
151.van Ommen, B, Wopereis, S, van Empelen, P et al. (2017) From diabetes care to diabetes cure-the integration of systems biology, ehealth, and behavioral change. Front Endocrinol 8, 381.
152.Kubota, H, Noguchi, R, Toyoshima, Y et al. (2012) Temporal coding of insulin action through multiplexing of the AKT pathway. Mol Cell 46, 820–832.